OECD Publishing, Paris. DOI:10.1787/9789264266438-en
This report discusses the need for an integrated and cyclical approach to managing health technology in order to mitigate clinical and financial risks, and ensure acceptable value for money.
The proliferation of high-cost drugs and rising drug prices are raising pressure on public health services. Governments need to work with industry and regulators to define a new way of approaching the development and use of new health technologies that encourage innovation while making it more affordable and that justifies better the benefit that it brings.
According to the study, "the launch of cancer and rare diseases drugs is rising, sometimes without an assessment of the increased benefits they produce for the health of patients. In this sense, the OECD exemplifies this situation in the case of the United States "where the launch price of cancer drugs per year of life gained has increased fourfold in just 20 years, in constant terms, and already exceeds $ 200,000 ".
Saturday, January 21, 2017
Subscribe to:
Posts (Atom)
